title: Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.
abstract: Cytomegalovirus (CMV)-specific immune reconstitution early after stem cell transplantation (SCT) was evaluated prospectively by detecting CD8+ T-cells, which recognize the peptide QYDPVAALF in the context of HLA-A*2402. Fifteen allogeneic SCT recipients were included in the study. All recipients and donors were seropositive for CMV and had the HLA-A*2402 allele. CMV-specific T-cells were detected as early as 1 month after transplantation, and their numbers increased to peak levels 2 to 5 months after transplantation. The numbers of CMV-specific T-cells in patients who developed grade II to IV acute graft-versus-host disease (GVHD) and received corticosteroids for acute GVHD were low in the early period after allogeneic SCT. There was a trend toward earlier reconstitution of CMV-specific CD8+ T-cells in allogeneic peripheral blood SCT (PBSCT) patients than in allogeneic bone marrow transplantation patients. The contribution of T-cells in the graft to the recovery of CMV-specific immune responses was also suggested by the finding that the reconstitution of CMV-specific CD8+ T-cells was delayed in CD34-selected autologous PBSCT compared with unpurged autologous PBSCT. The reconstitution of CMV-specific CD8+ T-cells was delayed in patients with CMV disease or recurrent CMV reactivation. These observations suggest that the detection of CMV-specific T-cells with an HLA-peptide tetramer is useful to assess immune reconstitution against CMV and to identify patients at risk for CMV disease or recurrent CMV reactivation after SCT.
authors.affiliation: Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan. gondo@hamanomachi.jp
authors.forename: Hisashi
authors.initials: H
authors.lastname: Gondo
authors.forename: Daisuke
authors.initials: D
authors.lastname: Himeji
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kamezaki
authors.forename: Akihiko
authors.initials: A
authors.lastname: Numata
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Tanimoto
authors.forename: Ken
authors.initials: K
authors.lastname: Takase
authors.forename: Kenichi
authors.initials: K
authors.lastname: Aoki
authors.forename: Hideho
authors.initials: H
authors.lastname: Henzan
authors.forename: Koji
authors.initials: K
authors.lastname: Nagafuji
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Ishikawa
authors.forename: Kazuya
authors.initials: K
authors.lastname: Shimoda
authors.forename: Shuichi
authors.initials: S
authors.lastname: Inaba
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tsukamoto
authors.forename: Takahiko
authors.initials: T
authors.lastname: Horiuchi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nakashima
authors.forename: Takeshi
authors.initials: T
authors.lastname: Otsuka
authors.forename: Koji
authors.initials: K
authors.lastname: Kato
authors.forename: Mika
authors.initials: M
authors.lastname: Kuroiwa
authors.forename: Masakazu
authors.initials: M
authors.lastname: Higuchi
authors.forename: Tsunefumi
authors.initials: T
authors.lastname: Shibuya
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Kamimura
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Kuzushima
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Tsurumi
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kanda
authors.forename: Mine
authors.initials: M
authors.lastname: Harada
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D049109:Cell Proliferation; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000276:immunology*; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000276:immunology; D015234:HLA-A Antigens / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007945:Leukemia, Lymphoid / Q000628:therapy; D007951:Leukemia, Myeloid / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000276:immunology*; D014184:Transplantation, Homologous
chemical_list: D000305:Adrenal Cortex Hormones; D018952:Antigens, CD34; D015234:HLA-A Antigens; D009842:Oligopeptides